Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting

Oncologist

Volumn 16, Issue 11, 2011, Pages 1487-1497

  Sartor, Oliver ^a   Michels, Ross M ^b   Massard, Christophe ^c   de Bono, Johann Sebastian ^c  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone; Androgen receptor; Cabazitaxel; Castration resistant prostate cancer (CRPC); Taxane

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ALPHARIDIN; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; AZD 3514; CABAZITAXEL; CUSTIRSEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPLERENONE; ESTRAMUSTINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IPILIMUMAB; MITOXANTRONE; ORTERONEL; PACLITAXEL; PLACEBO; POLYSORBATE 80; PREDNISOLONE; PREDNISONE; RADIUM 223; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RPR 116258; SATRAPLATIN; STEROID; TXD 258; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ANAPHYLACTIC SHOCK; ANEMIA; ANTINEOPLASTIC ACTIVITY; APPARENT MINERALOCORTICOID EXCESS SYNDROME; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RECHALLENGE; DRUG RESISTANCE; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; GLIOBLASTOMA; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOKALEMIA; IN VIVO STUDY; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; LIFE EXPECTANCY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL TIME; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ANDROSTENOLS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; HUMANS; MALE; NEOPLASM METASTASIS; PREDNISOLONE; PROSTATIC NEOPLASMS; RADIOISOTOPES; TAXOIDS; TISSUE EXTRACTS;

EID: 82355163158     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0412     Document Type: Review

References (65)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Bangma CH, Roemeling S, Schröder FH. Over-diagnosis and overtreatment of early detected prostate cancer. World J Urol 2007;25:3-9.
3. van Vugt HA, Bangma CH, Roobol MJ. Should prostate-specific antigen screening be offered to asymptomatic men? Expert Rev Anticancer Ther 2010;10:1043-1053.
4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitox-antrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
5. Tannock IF, de Wit R, Berry WR et al.; TAX 327 Investigators. Docetaxel plus prednisone or mi-toxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
6. Sternberg CN, Whelan P, Hetherington J et al.; Genitourinary Tract Group of the EORTC. Phase III trial of satraplatin, an oral platinum plus predni-sone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68:2-9.
7. Eymard JC, Oudard S, Gravis G et al. Do-cetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: A retrospective multicentre study. BJU Int 2010;106:974-978.
8. Wall ME, Wani MC. Camptothecin and taxol: Discovery to clinic-Thirteenth Bruce F. Cain Me-morial Award Lecture. Cancer Res 1995;55:753-760.
9. Oberlies NH, Kroll DJ. Camptothecin and taxol:Historic achievements in natural products re-search. J Nat Prod 2004;67:129-135.
10. Ahmed AA, Lu Z, Jennings NB et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 2010;18: 109-121.
11. Gan L, Chen S, Wang Y et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009; 69:8386-8394.
12. Jiang J, Huang H. Targeting the androgen receptor by taxol in castration-resistant prostate cancer. Mol Cell Pharmacol 2010;2:1-5.
13. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:12-23.
14. Childs S, Yeh RL, Hui D et al. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res 1998;58:4160-4167.
15. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent trans-porters. Nat Rev Cancer 2002;2:48-58.
16. Aller AW, Kraus LA, Bissery M-C. In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines [abstract 1923]. Proc Am Assoc Cancer Res 2000;41:303.
17. Bissery M-C, Bouchard H, Riou JF et al. Pre-clinical evaluation of TXD258, a new taxoid [ab-stract 1364]. Proc Am Assoc Cancer Res 2000;41: 214.
18. Gelmon KA, Latreille J, Tolcher A et al. Phase I dose-finding study of a new taxane, RPR 109881A, ad-ministered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol 2000;18:4098-4108.
19. Vrignaud P, Lejeune P, Chaplin D et al. In vivo efficacy of TXD258, a new taxoid, against hu-man tumor xenografts. Presented at the 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 1-5, 2000.
20. Bissery MC, Vrignaud P, Riou JF et al. In vivo isolation and characterization of a docetaxel resistant B16 melanoma. Proc Am Assoc Cancer Res 1995;36:316.
21. Dykes DJ, Sarsat JP, Bissery MC. Efficacy evaluation of TXD258, a taxoid compound, against orthotopic and subcutaneous glioblastomas. Presented at the 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 1-5, 2000.
22. Jevtana cabazitaxel [U.S. prescribing information]. Available at http://products.sanofi-aventis.us/jevtana/jevtana.pdf, accessed June 24,2011.
23. Mita AC, Denis LJ, Rowinsky EK et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15:723-730.
24. Bruno R, Vivier N, Vergniol JC et al. A population pharmacokinetic model for docetaxel (Tax-otere): Model building and validation. J Pharmacokinet Biopharm 1996;24:153-172.
25. Pivot X, Koralewski P, Hidalgo JL et al. A multicenter phase II study of XRP6258 adminis-tered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008;19:1547-1552.
26. de Bono JS, Oudard S, Ozguroglu M et al. Predni-sone plus cabazitaxel or mitoxantrone for metastatic cas-tration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lan-cet 2010;376:1147-1154.
27. Fitzpatrick JM, Anderson J, Sternberg CN et al. Optimizing treatment for men with advanced prostate cancer: Expert recommendations and the multidisciplinary approach. Crit Rev Oncol Hematol 2008; 68(suppl 1):S9-S22.
28. Reid AH, Attard G, Barrie E et al. CYP17 in-hibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5:610-620.
29. Ang JE, Olmos D, de Bono JS. CYP17 block-ade by abiraterone: Further evidence for frequent continued hormone-dependence in castration-resis-tant prostate cancer. Br J Cancer 2009;100:671-675.
30. Attard G, Belldegrun AS, de Bono JS. Selec-tive blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005; 96:1241-1246.
31. Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant pros-tate cancer. Eur Urol 2011;59:572-583.
32. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate can-cer: New agents for an established target. Lancet Oncol 2009;10:981-991.
33. Fizazi K, Massard C. New agents in metastatic prostate cancer. Eur J Cancer 2009;45(suppl 1): 379-380.
34. Chen CD, Welsbie DS, Tran C et al. Molecu-lar determinants of resistance to antiandrogen ther-apy. Nat Med 2004;10:33-39.
35. Knudsen KE, Scher HI. Starving the addic-tion: New opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009;15:4792-4798.
36. Attard G, Reid AH, Olmos D et al. Antitumor activity with CYP17 blockade indicates that castra-tion-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009;69:4937-4940.
37. Raghavan D, Klein EA. Prostate cancer: Moving forward by reinventing the wheel. but this time it is round. J Clin Oncol 2008;26:4535-4536.
38. Auchus RJ. Overview of dehydroepiandros-terone biosynthesis. Semin Reprod Med 2004;22: 281-288.
39. Barrie SE, Potter GA, Goddard PM et al. Phar-macology of novel steroidal inhibitors of cyto-chrome P450(17) ÷ (17 ÷-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267-273.
40. Potter GA, Barrie SE, Jarman M et al. Novel steroidal inhibitors of human cytochrome P45017 ÷ (17 ÷-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostatic cancer. J Med Chem 1995;38:2463-2471.
41. Rowlands MG, Barrie SE, Chan F et al. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 ÷-hydroxylase/C17,20-lyase (cytochrome P45017 al-pha) with resistance to esterase hydrolysis. J Med Chem 1995;38:4191-4197.
42. O'Donnell A, Judson I, Dowsett M et al. Hor-monal impact of the 17÷-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317-2325.
43. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone ace-tate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26:4563-4571.
44. Luthy IA, Begin DJ, Labrie F. Androgenic ac-tivity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 1988; 31:845-852.
45. Ryan CJ, Smith RM, Fong L et al. Phase I clin-ical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with cas-tration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28:1481-1488.
46. Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-3748.
47. Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-1501.
48. de Bono JS, Attard G, Reid AH et al. Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemo-therapy naïve and docetaxel pre-treated castration resistant prostate cancer (CRPC). J Clin Oncol 2008;26(15 suppl):5005.
49. Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-1495.
50. Ryan C, Efstathiou E, Smith M et al. Phase II multicenter study of chemotherapy (chemo)-naïve castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol 2009;27(15 suppl):5046.
51. Efstathiou E, Wen S, Molina A et al. Candidate predictors of response to abiraterone acetate in castrate-resistant prostate cancer [abstract 187]. Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, Orlando, Florida, February 26-28, 2009.
52. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
53. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-6309. Erratum in: Clin Cancer Res 2009;15:1506.
54. Olmos D, Arkenau HT, Ang JE et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience. Ann Oncol 2009;20:27-33.
55. Attard G, Swennenhuis JF, Olmos D et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69:2912-2918.
56. Attard G, Clark J, Ambroisine L et al.; Transatlantic Prostate Group. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-263.
57. Jhavar S, Brewer D, Edwards S et al. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int 2009;103:1256-1269.
58. Dehm SM, Schmidt LJ, Heemers HV et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008;68:5469-5477.
59. Guo Z, Yang X, Sun F et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69:2305-2313.
60. Taplin ME. Drug insight: Role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007;4:236-244.
61. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011;364:2055-2058.
62. Nilsson S, Franzén L, Parker C et al. Bonetargeted radium-223 in symptomatic, hormonerefractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587-594.
63. Chi KN, Hotte SJ, Yu EY et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:4247-4254.
64. BAYNEWS. Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients With Castration-Resistant Prostate Cancer That Has Spread to the Bone. The Bayer Press Server, 2011. Available at http://www.press.bayer.com/baynews/baynews.nsf/id/Alpharadin-Significantly-Improves-Overall-Survival-Phase-III-Trial-Patients-Castration-Resistant?Open&ccm_001, accessed June 13, 2011.
65. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.